Pay in 4 interest-free payments of $6.92 Learn more
Ships within 48 hours · Estimated delivery Sep 18 - Sep 23
glp-1/gip receptor agonist Role of a Dual Glucose-Dependent Insulinotropic Peptide (GIP)/Glucagon-like Peptide-1 (Twincretin) in Glycemic Control: From Pathophysiology to Treatment Metabolic Signaling Retatrutide is a triple-agonist Quantity:1-Bottle
Retatrutide is a triple-agonist (GLP-1 + GIP + glucagon) and recent clinical trials are showing remarkable outcomes in obesity treatment. 🔬 Latest data highlights: • ~25–30% average body-weight reduction in long-term trials
Atrium can help patients prepare by documenting BMI, weight-related conditions, prior treatment history, medication tolerance, labs, and the clinical reason a GLP-1 is being considered
Metabolic Signaling
Quantity:1-Bottle
And low-income Medicare beneficiaries who qualify for reduced cost sharing through the Part D Low-Income Subsidy can’t use those subsidies for GLP-1 prescriptions filled under the short-term program
US$ 23.87
US$ 29.94
US$ 28.68
US$ 29.30
US$ 21.06
